Big Pharma should go back to basics, says Novartis CEO

01/3/2013 | Wall Street Journal, The

Pharmaceutical companies shouldn't expect value creation simply by finding new ways to market existing drugs, says Novartis CEO Joseph Jimenez. Long-term growth can only come from a continuous stream of new treatments, he argues. "The industry needs to spend more money on R&D and less on sales and marketing," he says.

View Full Article in:

Wall Street Journal, The

Published in Briefs: